Close Menu

NHS

The funding will be used to start a new trial to assess the benefits of repeat population testing, expand existing trials, and increase PCR-based testing capacity.

The service is the first of its kind in the UK and relies on the Illumina NovaSeq 6000 platform to deliver results.

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.

The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.

In Nature this week: population sequencing led to rare disease diagnoses, analysis of marine green alga leads to discovery of new phylum, and more.

Because of coronavirus-related shutdowns of customer labs, the San Diego-based firm saw decreased revenues in all geographic regions, especially outside the US.

Balancing the Two

The Economist reports on an approach used by UK researchers to study medical records while protecting patient privacy.

Illumina will sequence 35,000 whole genomes for the Genetics of Mortality in Critical Care (GenOMICC) study and will provide an in-kind contribution.

The partners aim to identify signatures to predict the severity of disease in those infected and determine how patients will respond to therapies.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.